Bruce Power announced that building on the success of the new Isotope Production System install in its Unit 7 reactor, it and Isogen, are examining the feasibility of producing yttrium-90, used as a targeted liver cancer therapy.
Peter McDermid, Director of Isotopes and Site Energy Development says that the ability to irradiate medical isotopes presents a great opportunity for the world medical community and they are excited about doing their part to in helping to save lives.
President of Isogen, John D’Angelo says that Yttrium-90 is a promising medical isitope with a growing market and it represents a local next step for the expansion of their isotope production technology.
The two companies recently announced the launch of a Global Expressions of Interest Process for radiopharmaceutical organizations interested in locating in Ontario for isotope production.
The process is set to run until mid-2023.
